Therefore, we cannot exclude the influence of residual blasts and their interaction with NK cells, but in the case of KIR2DL3, the expression in patients with myeloid leukemia is usually rather elevated [38], suggesting the effect of the used chemotherapy, rather than the remaining blasts, on the level of KIR2DL3. This evidence concerns the gene KIR2DL3 and myeloid leukemia.